임상 한눈에 보기

• 6건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 2건 · 완료/종료 4건
• Phase: Phase 1, Phase 2 · Phase 1 · Phase 2
• Status: Active, not recruiting · Completed · Terminated
• 주요 endpoint: Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501A · Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501A · Phase 1b: Frequency and severity of ALLO-501A treatment-emergent adverse events (AEs) · serious AEs · and AEs of special interest
• 등록 대상자(표본 합산): 약 411명
• 선택한 코호트 보고 ORR: 0%
• 핵심: The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and …

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.